key: cord-0852821-bhelxxin authors: Sun, Yong; Ding, Chengchao; Chen, Qingqing; Xie, Jiajia; Yu, Junling; Shi, Yonglin; Jiang, Chengcheng; Zhang, Zhuhui; He, Hongliang; Ge, Yinglu; Li, Wenting; He, Jun; Gao, Yong title: Digital PCR assay for the effective detection of COVID-19 patients with SARS-CoV-2 low viral load date: 2021-05-26 journal: J Virol Methods DOI: 10.1016/j.jviromet.2021.114185 sha: 5f26909f3f1cfa3f5e96d89a6735d9ed08d26d2f doc_id: 852821 cord_uid: bhelxxin OBJECTIVE: Viral nucleic acid detection by real-time reverse transcription polymerase chain reaction (qPCR) is the current standard method for diagnosis of SARS-CoV-2 infection. However, due to low viral load in some COVID-19 patients, false negative results from this method have been repeatedly reported. METHOD: In this study, we compared the sensitivity and specificity of digital PCR (dPCR) in simulated samples and clinical samples with qPCR assay through a series of vigorous tests. RESULTS: The results showed that dPCR was more sensitive than qPCR especially for samples with low viral load (≤3 copies). In addition, dPCR had similar specificity as qPCR and could effectively distinguish other human coronaviruses and influenza virus from SARS-CoV-2. More importantly, dPCR was more sensitive than qPCR in detecting the virus in the “negative” samples from recurrent COVID-19 patients. CONCLUSIONS: In summary, dPCR could serve as a powerful complement to the current qPCR method for SARS-CoV-2 detection, especially for the samples with extremely low viral load, such as recurrent COVID-19 patients. The ongoing outbreak of 2019 novel coronavirus disease (COVID-19) caused by a new coronavirus, severe acute respiratory syndrome (SARS) coronavirus 2 (SARS-CoV-2), has spread rapidly across the world and became a public health emergency of international concern [1, 2] . Both human-to-human and asymptomatic transmission of SARS-CoV-2 infection through close contacts have been reported [3, 4] . Early diagnosis of COVID-19 is critical for prevention and control of virus infection and can help patients receive early treatment and prevent disease progression [5] . To date, viral nucleic acid detection by real-time reverse transcription polymerase chain reaction (qPCR) is regarded as the gold standard method for diagnosis of SARS-CoV-2 infection [6] [7] [8] . However, the sensitivity and reliability of qPCR has been questioned due to its false negative results in some clinically diagnosed patients who have exposure history, typical clinical symptoms, and typical image of CT scanning [9, 10] . Furthermore, recently, the recurrence of SARS-CoV-2 in discharged COVID-J o u r n a l P r e -p r o o f 19 patients has also been reported [9, 11] . Even though its mechanism is still unclear, the possible explanations might be false negative of detection, and reactivation or reinfection of the virus. Taking into account the fact that recurrence and asymptomatic COVID-19 patients usually have a very low viral load, a more sensitive detection method is urgently needed to improve the accuracy in identifying SARS-CoV-2 infected patients, in order to effectively prevent the virus transmission. Digital PCR (dPCR) is an absolute quantitative method that partitions the PCR reaction into a large number of smaller reactions and collect the intensity of fluorescence signals at the end point of each reaction [12, 13] . Unlike qPCR, dPCR does not depend on standard curves or relative threshold (CT) values for quantitation [14] and is more tolerant to PCR inhibitors [15] . The absolute quantification results come from Poisson statistics by counting the negative reactions followed by calculating the positive wells or the nucleic acid copies in the sample [16] . The high precision and the low limit of detection of dPCR could be used for detection of small variation of DNA or RNA copy number [17] , rare allele mutation [18] and gene fusion [19] . Recently, several studies reported that dPCR showed higher sensitivity and specificity in detecting low viral load of SARS-CoV-2 compared with qPCR [20-22]. However, the detectability for the samples with extremely low viral load, such as obtained from recurrent COVID-19 patients, remains unclear. In this study, we compared the sensitivity and specificity of dPCR with qPCR on simulated and clinical sputum samples. To analyze the detection efficacy of the low viral load samples, dPCR quantitative assay of SARS-CoV-2 were explored in clinically recurrent COVID-19 patients. Our findings demonstrated that in comparison with qPCR, dPCR was more sensitive with low viral load of both simulated and clinical SARS-CoV-2 samples and could accurately reflect the variation in copy number of viral RNA. The dPCR also showed high specificity in distinguishing the SARS-CoV-2 from other respiratory pathogens such as common influenza virus and other human coronaviruses. In addition, dPCR shows superiority over qPCR in detection of "recurrent" COVID-19 patients, which could be used as an important complement method for difficult or confusing samples in the clinic. The study protocol was approved by the medical ethics board of Anhui Center for Disease Control and Prevention (CDC). Please note that the study was performed on existing samples collected during standard diagnostic tests, posing no extra burden to patients. The dPCR assay was performed via the digital PCR chips (Thermofisher, cat#A26317) following the manufacturer's protocols, and QuantStudio 3D Digital The result was considered positive when the FAM signals of the SARS-CoV-2 target ≥ 3 with the VIC signals of the RNase P reference target ≥ 0, and negative when the FAM signals ≤ 2 with the VIC signals ≥ 60. If the FAM signals ≤ 2 with the VIC signals <60, the results were considered inconclusive and excluded. Concentrations of the target RNA sequences, along with their Poisson-based 95% confidence intervals were calculated by using the QuantStudio 3D Analysis Suite Cloud. qPCR was conducted with primers and probes targeting the ORF1ab (FAM) and N gene (VIC). Reaction system and amplification conditions were carried out according to the manufacturer's specifications (BioGerm, China). A 25μl of reaction J o u r n a l P r e -p r o o f mixture contained 12μl of reaction buffer, 4μl of mixed enzymes, 4μl of ORF1ab/N reaction mixture and 5μl of nucleic acid from each sample. Thermal cycling was performed at 50°C for 10 min for reverse transcription, followed by 95°C for 5min (pre-denaturation) and then 40 cycles of 95°C for 10sec (denaturation) and 55°C for 40sec (extension) in Applied Biosystems ABI 7500 real time PCR system (Thermo In the present study, we first investigated whether dPCR and qPCR assays could equally effectively detect SARS-CoV-2 virus in low and moderate concentrations. To do so, low and moderate positive simulated samples were prepared by diluting the authenticSARS-CoV-2 into the negative matrix to 3-6 copies per reaction as low viral load samples (20 samples) and 9-15 copies per reaction as moderate viral load samples (10 samples) which were subjected to both dPCR and qPCR assays. As shown in Fig 1A, the positive rates of the low and moderate positive samples were 100% for either dPCR or qPCR assays. When analyzing the values of the low and moderate positive samples detected by dPCR assay, it showed they were largely in the range of the copy number of the virus in the respective samples ( Fig 1B) . We next compared the dPCR and qPCR for their limit of sensitivity of detection of SARS-CoV-2 by using serial dilution of authentic SARS-CoV-2 spiked into the negative matrix. A two-phase approach was used to determine the limit of detection (LOD). In phase I, the preliminary LOD was established through diluting the authentic SARS-CoV-2 into different concentrations. To do so, a total of 5 dilutions were created at 0.375, 0.75, 1.5, 3 and 6 copies of viral RNA with three replicates per concentration. As shown in Fig 2A and B , when the virus was diluted between 3 and 6 copies per reaction, the positive rate was 100% for both dPCR and qPCR. At concentration of 1.5, 0.75, and0.375 copies per reaction, dPCR was still able to obtain the positive results (66.67% for 1.5 copies, 33.33% for 0.75 copies, and 66.7% for 0.375 copies) while qPCR failed to detect any positive signals at any concentration of the samples, indicating that dPCR is more sensitive in detecting SARS-CoV-2 when the viral copy number is below 3. To further elaborate the sensitivity of the assays, both dPCR and qPCR were used to test 20 replicates on simulated samples of 3 copies of SARS-CoV-2. The dPCR assay showed positive rate at 95% (19/20) while qPCR at 90% (18/20) (Fig 2C) , indicating that the dPCR was more sensitive than qPCR for samples with viral load around 3 copies. To test the specificity of dPCR and qPCR assays, six negative lower respiratory tract clinical samples were mixed together to act as a matrix of negative samples in which the quantified reference N gene RNA was added to prepare the low positive simulated samples. The matrix negative samples (20 replicates for dPCR and 21 replicates for qPCR) and low positive simulated samples (3-6 copies per reaction, 20 replicates for both dPCR and qPCR) were used to compare the specificity between qPCR and dPCR. The negative samples tested by qPCR and dPCR were all "negative". Among the positive samples, 85.71% (18/21) were tested positive (≥3 copies) by dPCR while only 75% (15/20) were tested positive (CT<35) by qPCR ( Fig 3A) . As shown in Fig 3B, the FAM signals of dPCR were all below the threshold of 3. Thus, the dPCR assay showed a consistent specificity while performing higher sensitivity than qPCR. To investigate the possible difference of dPCR and qPCR assays in clinical use, we performed a parallel analysis using positive clinical sputum specimens with CT value at 20 from previous qPCR assay of four confirmed COVID-19 patients. The samples were serially diluted at 1:10 dilution, and a total of 5 dilutions for each specimen were prepared and subjected to dPCR and qPCR assays. The results showed that the dilutions ranged from 10 -1 to 10 -5 were all detected positive by both dPCR and qPCR. However, for the dilutions of 10 -6 , there were 4/4 (100%) samples were detected positive by dPCR, while 2/4 (50%) positive by qPCR ( Table 1 ). The CT value of qPCR was strongly correlated with the serial dilutions from 10 -1 to 10 -5 for the 4 samples (R 2 =0.99102±0.00552). In the meantime, the FAM value of dPCR was also strongly correlated, but to a less degree than qPCR, with the serial dilutions (R 2 =0.9498±0.04167) (Fig 4) . These results indicated that both dPCR and qPCR were able to accurately reflect the variation in concentration of SARS-CoV-2 samples. To further validate the specificity of dPCR assay, the samples of influenza virus and other human coronaviruses of respiratory pathogen were collected and detected by dPCR. As shown in Table 2 Finally, to test whether dPCR can be applied to effectively detect the samples J o u r n a l P r e -p r o o f from suspected recurrent COVID-19 patients, a total of 18 "negative" samples from 17 such patients including 9 throat swabs, 6 sputum samples, and 3 anal swabs, were tested by dPCR and re-tested by qPCR. Two positive samples were used as controls (Number 1 and 2) . The results of dPCR assay were contrastively analyzed with the qPCR results. As shown in Table 3 It was reported that around 60% of SARS-CoV-2 infections were asymptomatic In this study, we first tested the detection efficacy of dPCR and qPCR assays on J o u r n a l P r e -p r o o f low (3-6 copies) and middle (9-15 copies) simulated SARS-CoV-2 samples, and found that the two assays gave consistent results for both samples and dPCR was able to accurately reflect the copy number in the respective samples. We then compared the sensitivity of dPCR with qPCR on simulated and clinical sputum samples and the results showed that dPCR was more sensitive when the viral copy number is below 3 (lower threshold than qPCR) in the simulated or clinical samples. In the meantime, the serial dilutions with CT value and FAM value are both strongly correlated with the former slightly higher, indicating that both dPCR and qPCR could accurately reflect the variation in the concentration of SARS-CoV-2 virus in the samples. In regard to the testing specificity, dPCR obtained absolute negative signals (FAM value=0) for 14/20 (70%) of negative samples. However, it did give certain positive signals (1-2 copies per reaction) in 6/20 (30%) negative samples (Fig. 3B) . Nevertheless, when using 2 copies as the cutoff value, dPCR showed 100% specificity, same as qPCR, in testing negative clinical samples (Fig. 3A) . By using this threshold, dPCR could effectively distinguish the SARS-CoV-2 from other respiratory pathogens such as common influenza virus and other human coronaviruses (Table 3 ). In addition, three of 21 positive samples were not detected by dPCR while 5 of them were not detected by qPCR, which indicated that the sensitivity of dPCR is higher than qPCR in detecting SARS-CoV-2 (Fig. 3B) . Notably, the FAM value of 3 "negative samples" was not absolute negative signals. It is suggested that we should attaches more importance to "negative samples" with FAM value signals. Recently In this study, we compared the difference of the two assays in detecting the "negative" samples from clinically recurrent COVID-19 patients. Seven "negative" samples, including 1 sputum samples, 4 throat swab samples and 2 anal swab samples, were identified positive by dPCR assay but not by qPCR assay. On the contrary, only 2 throat swab samples were tested positive by qPCR assay but not by dPCR assay. More importantly, most of the dPCR identified positive samples could not be detected even subjected to the second qPCR test. Therefore, our study clearly demonstrated that dPCR was superior over qPCR in detecting difficult or confusing samples with extremely low viral load from "recurrent" or convalescent COVID-19 patients, suggesting that the more sensitive assay, e.g. dPCR, is a powerful tool to help rule out the false negative results to avoid discharge of COVID-19 patients who might still have the virus becoming active source of the disease. Our study demonstrated that in comparison with qPCR, dPCR is more sensitive We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Anhui province. We thank the Chinese National Health Commission for coordinating data collection for patients with COVID-19. The authors have no conflicts of interests to declare. The FAM values of the negative and low positive samples detected by dPCR. Note: * The "+" is positive, the "-" is negative. J o u r n a l P r e -p r o o f Note: *The "-" is negative. J o u r n a l P r e -p r o o f Note: # Positive control samples; * The "-" is negative. Clinical features of patients infected with 2019 novel coronavirus in Coronavirus Diseases (COVID-19) Current Status and Future Perspectives: A Narrative Review Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany Real-time RT-PCR in COVID-19 detection: issues affecting the results Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia A Novel Coronavirus from Patients with Pneumonia in China Preliminary study of the relationship between novel coronavirus pneumonia and liver function damage: a multicenter study False-negative of RT-PCR and prolonged nucleic acid conversion in COVID-19: Rather than recurrence Potential false-negative nucleic acid testing results for Severe Acute Respiratory Syndrome Coronavirus 2 from thermal inactivation of samples with low viral loads Clinical infectious diseases : an official publication of the Infectious Diseases Society of America rRNA Gene Using Digital PCR Digital Assays Part I: Partitioning Statistics and Digital PCR Assessment of the real-time PCR and different digital PCR platforms for DNA quantification Tolerance of droplet-digital PCR vs real-time quantitative PCR to inhibitory substances Highly precise measurement of HIV DNA by droplet digital PCR We acknowledge all health-care workers involved in the diagnosis and treatment of patients in Anhui province. We thank the Chinese National Health Commission for coordinating data collection for patients with COVID-19 J o u r n a l P r e -p r o o f YS, CD, QC, JX, JY and CJ collected the epidemiological, and performed the experiments. YS, ZZ, HH, YG and WL contributed to clinical and laboratory data acquisition and analysis. JH, CD and YG drafted the manuscript. YS, JH and YG had the idea for the study and take responsibility for the integrity of the data and the accuracy of the data analysis. The study was approved by the Institutional Review Board Ethics Committee of University of Science and Technology of China. Written informed consent was obtained from each patient. The authors have no conflicts of interests to declare.